Management's previous 1H guidance of 20% NPAT was spot on, today's price fall is due to the FY18 25% NPAT guidance, as I posted earlier it means 2H will be 30% compared to 2H FY17.
The question is what the company will do to stop the market share loss and whether it will be effective in its attempt?
Ann: Monash IVF Group 1H18 Results Presentation, page-7
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MVF (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.38 |
Change
0.000(0.00%) |
Mkt cap ! $537.6M | |||
| Open | High | Low | Value | Volume |
| $1.38 | $1.40 | $1.38 | $531.2K | 382.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4994 | $1.38 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.39 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| MVF (ASX) Chart |